Inclusion Criteria:

   - Patients must be =< 21 years of age when registered on study for dose levels -1 to 5
   and Expansion Cohort 1; patients age 22-30 years of age at time of study registration
   are eligible for Expansion Cohort 2

   - Patients must have a diagnosis of neuroblastoma either by histologic verification of
   neuroblastoma and/or demonstration of tumor cells in the bone marrow with increased
   urinary catecholamines

   - Patients must have high-risk neuroblastoma

   - Patients must have at least ONE of the following:

      - Recurrent/progressive disease at any time; biopsy not required, even if partial
      response to intervening therapy

      - Refractory disease (i.e. less than a partial response to frontline therapy,
      including a minimum of 4 cycles of chemotherapy); no biopsy is required to
      document eligibility

      - Persistent disease after at least a partial response to frontline therapy (i.e.
      patient has had at least a partial response to frontline therapy but still has
      residual disease by metaiodobenzylguanidine [MIBG] scan, computed tomography
      [CT]/magentic resonance imaging [MRI], or bone marrow aspirates/biopsies);
      patients in this category are REQUIRED to have histologic confirmation of viable
      neuroblastoma from at least one residual site; tumor seen on routine bone marrow
      morphology is sufficient; bone marrow immunocytology alone is not sufficient for
      eligibility

   - Patients must have at least ONE of the following sites of disease (excluding those
   patients entered in the Expansion Cohort) :

      - Measurable tumor on MRI or CT scans or X-ray; measurable is defined >= 20 mm in
      one dimension; for spiral CT defined as >= 10 mm in one dimension; for patients
      with persistent disease, a biopsy of site seen on CT/MRI must have demonstrated
      viable neuroblastoma; if the lesion was radiated, then biopsy must be done >= 4
      weeks after radiation completed

      - MIBG scan with positive uptake at a minimum of one site; for patients with
      persistent disease, a biopsy of an MIBG positive site must have demonstrates
      viable neuroblastoma; if the lesion was radiated, then biopsy must be done >= 4
      weeks after radiation completed

      - Bone marrow with tumor cells seen on routine morphology (not by neuron specific
      enolase [NSE] staining only) of one bone marrow sample of a bilateral aspirate
      and/or biopsy

   - Patients entered in the Expansion Cohorts 1 or 2 who have had a prior relapse are
   eligible with no measurable or evaluable sites of tumor (i.e. in second complete
   response)

   - Patients must have a life expectancy of at least 6 weeks and a Lansky (=< 16 years) or
   Karnofsky (> 16 years) score of at least 50

   - Patients must have fully recovered from the acute toxic effects of all prior
   chemotherapy, immunotherapy, or radiotherapy prior to study enrollment

   - Must have received last dose of myelosuppressive chemotherapy at least 3 weeks prior
   to start of vorinostat; this includes cytotoxic agents given on a low dose metronomic
   regimen

   - Must have received last dose of biologic (anti-neoplastic agent) (includes retinoids)
   at least 7 days prior to start of vorinostat

   - Must have received last dose of monoclonal antibodies at least 7 days or 3 half-lives,
   whichever is longer, prior to start of vorinostat

   - Patients must not have received radiation (small port) for a minimum of two weeks
   prior to start of vorinostat; for patients with only one site of measurable or
   evaluable disease, radiation must not have been given to that site unless that site
   has demonstrated clear progression after radiation

   - A minimum of 12 weeks prior to start of vorinostat is required following prior large
   field radiation therapy (i.e. total body irradiation, craniospinal, whole abdominal,
   total lung, > 50% marrow space), otherwise a minimum of 6 weeks must have elapsed if
   other substantial bone marrow (BM) radiation

   - Patients are eligible 6 weeks after date of autologous stem cell infusion following
   myeloablative therapy (timed from start of vorinostat); patients are eligible 6 weeks
   after date of allogeneic stem cell transplant if without evidence of active graft
   versus host disease; patients receiving an autologous stem cell infusion to support
   non-myeloablative therapy are eligible at any time as long as they meet the
   hematologic and other organ function criteria for eligibility

   - A minimum of 6 weeks must have elapsed after 131I-MIBG therapy (timed from start of
   vorinostat)

   - All cytokines or hematopoietic growth factors must be discontinued a minimum of 7 days
   prior to enrollment on this protocol

   - Patients must not be receiving any other anti-cancer agents or radiotherapy at the
   time of study entry or while on study

   - Patients must not be receiving other investigational medications (covered under
   another investigational new drug [IND]) within 30 days of study entry or while on
   study

   - Since valproic acid has histone deacetylase (HDAC) inhibitory activity, patients must
   not have received valproic acid within 30 days of study entry

   - Prolongation of the corrected QT (QTc) interval has been rarely observed in adults
   receiving vorinostat; patients must not be receiving azole anti-fungal therapy at the
   time of study entry or while on protocol therapy; additional agents known to prolong
   the QTc interval should be avoided unless therapeutic alternative medications are not
   available

   - Patients must not be receiving pentamidine therapy for Pneumocystis pneumonia (PCP)
   prophylaxis at the time of study entry or while on protocol therapy

   - No hematopoietic growth factors within 7 days of enrollment on this protocol

   - Patients must not be receiving enzyme-inducing anti-convulsant therapy

   - Hemoglobin >= 8 g/dL (transfusion allowed)

   - Absolute neutrophil count (ANC) >= 750/uL for patients without marrow metastases at
   study enrollment; ANC >= 500/uL for patients with marrow metastases at study
   enrollment

   - Platelet count >= 50,000/ul, transfusion independent (no platelet transfusions within
   1 week)

   - Patients with known bone marrow metastatic disease will be eligible for study as long
   as they meet hematologic function criteria; patients with marrow disease are not
   evaluable for hematologic toxicity; if dose limiting hematologic toxicity occurs in
   two patients, then all subsequent patients enrolled must be evaluable for hematologic
   toxicity, therefore patients with marrow metastases will be ineligible

   - Serum creatinine based on age as follows:

      - 0.8 mg/dL (=< 5 years of age)

      - 1.0 mg/dL (> 5 and =< 10 years of age)

      - 1.2 mg/dL (> 10 and =< 15 years of age)

      - 1.5 mg/dL (> 15 years of age)

   - Patient must have a urinalysis with no more than 1+ hematuria and/or no more than 1+
   proteinuria

   - Total bilirubin =< 1.5 x upper limit of normal for age

   - Serum glutamate pyruvate transaminase (SGPT) (alanine aminotransferase [ALT]) and
   serum glutamic oxaloacetic transaminase (SGOT) (aspartate aminotransferase [AST}) < 3
   x upper limit of normal (note that for ALT, the upper limit of normal for all sites is
   defined as 45 U/L)

   - Alkaline phosphatase =< 2.5 times upper limit of normal

   - Normal ejection fraction (>= 55%) documented by either echocardiogram or radionuclide
   multi gated acquisition scan (MUGA) evaluation OR normal fractional shortening (>=
   27%) documented by echocardiogram

   - Corrected QT (QTc) interval =< 450 msec

   - Serum triglyceride =< 300 mg/dL

   - Serum calcium < grade 2

   - All post-menarchal females must have a negative beta-human chorionic gonadotropin
   (HCG); males and females of reproductive age and childbearing potential must use
   effective contraception for the duration of their participation

   - Patients with other ongoing serious medical issues must be approved by the study chair
   prior to registration

   - Patient and/or parent must have the ability to understand and the willingness to sign
   a written informed consent document

Exclusion Criteria:

   - Pregnancy, breast feeding, or unwillingness to use effective contraception during the
   study; women of child-bearing potential and men must agree to use adequate
   contraception (hormonal or barrier method of birth control; abstinence) prior to study
   entry and for the duration of study participation; should a woman become pregnant or
   suspect she is pregnant while participating in this study, she should inform her
   treating physician immediately

   - Patients who, in the opinion of the investigator, may not be able to comply with the
   safety monitoring requirements of the study

   - Patients with disease of any major organ system that would compromise their ability to
   withstand therapy

   - Patients with an active or uncontrolled infection; patients on prolonged antifungal
   therapy are still eligible if they are culture and biopsy negative in suspected
   radiographic lesions and meet other organ function criteria

   - Patients receiving enzyme-inducing anti-convulsants, pentamidine or azole anti-fungal
   therapy

   - Prior treatment with vorinostat combined with cisRA is not allowed; prior therapy with
   either vorinostat or cis-retinoic acid single agent or combined with alternative
   agents is allowed

   - Patients with a paraben allergy cannot take cisRA preparations containing this
   compound (i.e., Accutane, Sotret) but are eligible if they can take an alternate
   preparation without paraben